Deals
Sartorius to Buy French Biotech Polyplus for $2.6 Billion
- Deal would bolster Sartorius’s drug-delivery technologies
- Sartorius shares fall about 7% after news of the deal
A researcher handles a Sartorius AG Biostat B plus bioreactors
Photographer: Ore Huiying/BloombergThis article is for subscribers only.
Sartorius Stedim Biotech agreed to buy Polyplus, a maker of components for cell and gene therapies, for about €2.4 billion ($2.6 billion) from a group of private investors.
The deal would bolster Sartorius’s portfolio of drug-delivery technologies, creating a deeper focus on the fast-growing field of viral vectors, which are tools used to deliver genetic material into cells.